Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination

Ijlal Uddin
Shakil Aslam
Division of Nephrology and Hypertension, Georgetown University Hospital, Washington, District of Columbia, USA

Abstract: Hypertension is a major health problem worldwide and remains underdiagnosed and undertreated. Although public awareness and control of hypertension have improved over the last decade, only one-third of hypertensive patients achieve the rather conservative blood pressure (BP) goal of $<140/90$ mmHg. Most hypertensive patients require more than one drug for optimum BP control. Expert panels recommend use of combination therapy with two or more medications for Stage 2 and higher hypertension and in high-risk patients. However, the use of multiple drugs reduces patient compliance. Fixed-dose combination therapy helps improve patient compliance and thus achieve the target BP. Dose titration of the individual constituent drugs is recommended before switching to an equivalent fixed-dose combination. Randomized, controlled trials have shown that the fixed-dose combination of amlodipine–olmesartan medoxomil is more effective in lowering BP than monotherapy with either of these agents, with a similar side effect profile.

Keywords: hypertension, target blood pressure, compliance, amlodipine, olmesartan

Introduction

Uncontrolled hypertension is the leading risk factor for cardiovascular disease and mortality worldwide. In 2000, approximately one billion people worldwide had hypertension, and this number is expected to increase by 60% to a total of 1.56 billion by 2025. Hypertension affects approximately 30% of adults in the industrialized nations, and blood pressure (BP) reduction to the recommended levels of $<140/90$ mmHg remains low at 32%. Even in patients with chronic kidney disease who have higher risk of cardiovascular disease and associated co-morbidities, only 36.8% achieve the BP target recommended by the Joint National Committee on Prevention, Evaluation, and Treatment of High BP (JNC-7). Effective BP control to $<140/90$ mmHg reduces the incidence of heart failure by 50%, myocardial infarction by 25%, and stroke by 40%.

The continued poor rates of BP control indicate a persistent need for improved antihypertensive therapy. Recent and ongoing clinical trials are utilizing combination therapy as initial treatment, especially in stage 2 hypertension (160 mmHg systolic or higher, diastolic 100 mmHg or higher), or higher degrees of hypertension, or if BP is $>20/10$ mmHg above the target. Combination therapy may potentially confer the advantage of improved efficacy through additive or synergistic effects. Rational add-on therapies to renin–angiotensin–aldosterone system inhibitors include thiazide diuretics (especially in hypertensive patients exhibiting a low-renin state, eg, Afro-Caribbean and black...
Advantages of combination therapy

Better blood pressure control

Initiating therapy with two agents is recommended for patients at high risk of a cardiovascular event or those with BP > 20/10 mmHg above goal (Table 1). A rational strategy is to use agents with complementary mechanisms of action to enhance BP-lowering efficacy and prevent target organ damage. In experimental models, the combination of a calcium channel blocker with an agent that blocks angiotensin II improves endothelial function, inflammation, ventricular remodeling, and renal function to a greater degree than these drugs given as monotherapy. Several large randomized trials have shown that monotherapy is ineffective in reducing BP to a predetermined target range. For instance, in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) trial, only 27% of 42,418 participants achieved the goal BP (<140/90 mmHg) on monotherapy, from a baseline mean systolic BP of 146 mmHg and 156 mmHg for previously treated and untreated patients, respectively. In the Losartan Intervention For Endpoint (LIFE) trial, 90% of 9193 participants with hypertension and left ventricular hypertrophy required more than one antihypertensive agent to achieve a similar BP target (<140/90 mmHg) from a mean baseline of 174/97.8 mmHg. In the Avoiding Cardiovascular events through COMbination therapy in Patients LLiving with Systolic Hypertension (ACCOMPLISH) trial, 32.3% of participants treated with benazepril–amlodipine or benazepril–hydrochlorothiazide required additional antihypertensive agents to reach the target BP of <140/90 mmHg (<130/80 mmHg for patients with chronic kidney disease) from a baseline of 145/80 mmHg. In this randomized double-blind trial, the target BP (<140/90 mmHg) was achieved in over 78% of patients in the US cohort on the amlodipine–benazepril combination. In diabetics and in patients with chronic kidney disease the control rates were 72.5% and 70.8%, respectively. These results demonstrate that monotherapy is ineffective in achieving the target BP in the majority of hypertensive individuals. This is reflected in the recommendations by several advisory panels (Table 1). The JNC-7 guidelines recommend initiating therapy with two antihypertensive agents in patients with Stage 2 and higher levels of BP. The European Society of Hypertension also recommends initial combination antihypertensive therapy in patients at high cardiovascular risk. Calcium channel blockers and antagonists of angiotensin II are highly effective and widely used antihypertensive agents, and are being increasingly offered in fixed-dose combinations. In addition to lowering BP, these drugs have vasculoprotective and pleiotropic properties.

Better compliance with antihypertensive therapy

Patient adherence to prescribed therapy and advice is a strong predictor of achieving BP control. The number of medications prescribed and the complexity of the treatment regimen are two important determinants of patient adherence. This has been shown in patients with a variety of different diseases. Adherence improves with fewer medications or pills prescribed. Reducing the number of pills by using combinations of drugs reduces non-adherence compared with the same drugs given separately, even with the same frequency. A meta-analysis of nine studies comparing fixed-dose combinations versus the same drugs given separately for treatment of diabetes, hypertension, tuberculosis, and human immunodeficiency virus infection, reported that fixed-dose combinations reduce the rate of non-adherence by 26%. In this meta-analysis, a subgroup analysis of the four studies in hypertension showed that the fixed-dose combinations decreased the risk of medication non-adherence by 24% compared with free-drug combinations. In a study of 198 hypertensive patients randomized to receive diltiazem twice daily or amlodipine once daily, the

### Table 1 Guidelines for initial combination therapy

<table>
<thead>
<tr>
<th>Committee</th>
<th>BP levels requiring initial combination therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNC-7&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Stage 2 (≥160/100 mmHg) SBP &gt; 20 mmHg or DBP &gt; 10 mmHg above the goal</td>
</tr>
<tr>
<td>NKF&lt;sup&gt;34&lt;/sup&gt;</td>
<td>SBP &gt; 20 mmHg above the goal according to the stage of CKD and CVD risk</td>
</tr>
<tr>
<td>ADA&lt;sup&gt;27&lt;/sup&gt;</td>
<td>BP &gt; 130/80 mmHg and Type 2 diabetes</td>
</tr>
<tr>
<td>ESH&lt;sup&gt;10&lt;/sup&gt;</td>
<td>High-risk patients according to total CVD risk</td>
</tr>
</tbody>
</table>

**Abbreviations:** JNC-7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; NKF, National Kidney Foundation; ADA, American Diabetes Association; ESH, European Society of Hypertension; CKD, chronic kidney disease; CVD, cardiovascular disease; BP, blood pressure.

### Table 2 Benefits of combination therapy in hypertension

- Better adherence to therapy and simplification of the therapeutic regimen
- Better blood pressure control than monotherapy
- Avoidance of dose-dependent adverse effects seen with higher doses of single agents
- Attenuation of the adverse effects of some agents when used alone
- Complementary/synergistic vasculoprotective or pleiotropic effects.
patients on a once-daily regimen took their study drug on a
regular schedule 86%±2% of times compared with 76%±2%
for those who were on a twice-daily dosing schedule.16 In
a retrospective analysis of data from a pharmacy claims
database in the US,17 adherence to a fixed-dose combination
of amlodipine–benazepril was compared with adherence to
free-dose combination therapy of the two agents. Patients
given two or more prescriptions for the fixed-dose combina-
tion (n = 2839) or the two components separately (n = 3367)
were identified and followed up for an average of 259 days and
247 days, respectively. Adherence to fixed-dose combination
therapy (88%) was significantly greater than for free combina-
tion therapy (69%). The average annual cost of cardiovascular
disease-related care per subject was also significantly lower in
patients receiving the fixed-dose combination. Other studies
have shown that adherence in hypertensive patients is inversely
related to the BP control achieved.13

Fixed-dose combination
of amlodipine–olmesartan
medoxomil

The antagonists of angiotensin II have favorable metabolic,
renal, cardiovascular, and quality of life effects compared
with other antihypertensive agents. A post hoc analysis of
the ACCOMPLISH trial reported that initial treatment
with benazepril plus amlodipine slowed the progression of
nephropathy to a greater extent than benazepril plus hydro-
chlorothiazide. Currently, the angiotensin II blockers are
recommended as first-line drugs in patients with diabetes,
proteinuria, and systolic heart failure. These drugs reduce
BP and proteinuria, and slow the progression of diabetic
nephropathy.18 In patients with Type 2 diabetes and overt
nephropathy, the renoprotective action of angiotensin recep-
tor blockers was evident in two large-scale trials. RENAAL
(Reduction of Endpoints in non-insulin dependent diabetes
mellitus [NIDDM] with the Angiotensin II Antagonist Losar-
tan Study)19 demonstrated a 16% risk reduction in the primary
composite endpoint of doubling of baseline serum creatinine,
end-stage renal disease, or death from a cardiovascular cause,
with losartan compared with placebo. The Irbesartan Diabetic
Nephropathy Trial (IDNT)20 demonstrated superiority of irbe-
sartan compared with amlodipine and conventional therapy in
prevention of doubling of baseline serum creatinine, develop-
ment of end-stage renal disease, or all-cause mortality, with
similar BP reduction across all three cohorts.

Calcium channel blockers are effective in lowering BP
and among the most commonly used antihypertensive drugs.
Therefore, the angiotensin II antagonists are increasingly
being used with calcium channel blockers as a fixed-dose
combination. The fixed-dose combination of olmesartan–
amlopidine is the focus of this review. A brief discussion of
the individual components will be followed by a discussion of
the efficacy and tolerability of the fixed-dose combination
of these agents.

Amlodipine

Amlodipine is a third-generation dihydropyridine calcium
channel blocker and is the most commonly used agent in its
class. More than 90% of amlodipine is absorbed and 95% of
circulating amlodipine is bound to plasma proteins. Due
to lack of significant first-pass hepatic metabolism, it has a
prolonged duration of action, with a half-life of 35–45 hours.
Like other calcium channel blockers, it acts by decreasing
Ca2+ entry to cells through L-type Ca2+ channels, resulting
in vascular smooth muscle relaxation. Its action peaks at
10–14 hours and steady-state plasma levels are reached in
7–8 days. About 90% of amlodipine is converted to inactive
metabolites via hepatic metabolism, and 60% of the metabo-
lites are excreted in the urine. In patients with kidney disease,
the pharmacokinetics of amlodipine are minimally changed.
Dose adjustment may be needed in hepatic disease. Another
property unique to amlodipine (with the possible exception
of azelnidipine, not available in the US) is its antioxidant
activity. Amlodipine is superior to felodipine, diltiazem,
verapamil, and captopril at pharmacologically relevant
doses in inhibiting lipid peroxidation in isolated membrane
vesicles enriched with polysaturated fatty acids.21 This
antioxidant property of amlodipine is independent of calcium
channel blockade and is related to its chemical structure and
direct physicochemical interactions with the membrane lipid
bilayer. Due to its high lipophilicity, amlodipine is highly
concentrated in the cell membrane, which enables it to scav-
enge free radicals effectively and break the lipid peroxidation
chain reaction. Two abstractable hydrogen atoms associated
with its aromatic rings further enhance its antioxidant
activity.22 There is also evidence that amlodipine modulates
the activity of PKC-α, a powerful activator of nicotinamide
adenine dinucleotide phosphate oxidase.

Amlodipine is very effective in lowering BP and reduces
cardiovascular disease morbidity and mortality. This was
shown in ALLHAT,23 which randomized 42,418 high-risk
patients to receive chlorthalidone, amlodipine, lisinopril, or
doxazosin. The study participants were >55 years of age, had
Stage 1 or 2 hypertension with one additional cardiovascu-
lar disease risk factor, and 36% had diabetes. In this study,
amlopidine was as effective as chlorthalidone in reducing the
primary combined endpoint of fatal coronary heart disease or nonfatal myocardial infarction (relative risk, 0.98; 95% confidence interval 0.90–1.07). Its efficacy in reducing combined coronary heart disease events and end-stage renal disease was comparable with that of chlorthalidone. However, the incidence of heart failure was 38% higher in patients assigned to amlodipine than in those assigned to chlorthalidone in the absence of concomitant angiotensin II inhibitor therapy in either group. The incidence of other adverse effects was similar in both groups. In the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial,\textsuperscript{24} amlodipine was more effective than valsartan in reducing the prespecified secondary endpoint of fatal and nonfatal myocardial infarction (4.1% versus 4.8%, \(P = 0.02\)). Overall, there were no differences in the primary composite endpoint of the time to first cardiac event. In this study systolic BP control (\(<140/90\) mmHg) was achieved in 4392 (58%) of patients on valsartan and 4793 (64%) of those on amlodipine. Diastolic BP (\(<90\) mmHg) control was achieved in 6652 (88%) and 6940 (92%) for valsartan and amlodipine, respectively. The target BP (\(<140\) mmHg systolic and \(<90\) mmHg diastolic) was achieved in 4274 (56%) patients in the valsartan group and 4694 (62%) in the amlodipine group. The baseline BP in both groups was 154/88 mmHg. Both treatments were well tolerated. The incidence of edema was twice as high in amlodipine-treated patients (32.9%) as in valsartan-treated patients (14.9%), and hypokalemia was seen in the 6.1% of the patients treated with amlodipine versus 3.2% in the valsartan-treated group. A later substudy analysis of 7080 participants, analyzed according to whether they were still on monotherapy at the end of the first six months, showed that amlodipine increased the risk of congestive heart failure by 22%,\textsuperscript{25} although the original analysis had shown no difference. Both of these large randomized trials suggested a higher risk of new onset congestive heart failure with amlodipine monotherapy. However, in patients with pre-existing congestive heart failure, addition of amlodipine does not increase mortality or morbidity.\textsuperscript{26} Furthermore, the increased risk of congestive heart failure seen with amlodipine monotherapy may be neutralized when it is combined with an angiotensin II antagonist.\textsuperscript{27}

### Olmesartan medoxomil

Olmesartan medoxomil, a prodrug hydrolyzed to olmesartan during absorption from the gastrointestinal tract, is a specific angiotensin II Type I receptor (AT\(_{1}\)R) antagonist. Olmesartan medoxomil has 12,500-fold greater affinity for the AT\(_{1}\) receptor than for the AT\(_{2}\) receptor. Olmesartan medoxomil has doses ranging from 2.5 mg to 40 mg. The duration of inhibitory effect is related to the dose, with doses of olmesartan medoxomil \(>40\) mg giving \(>90\%\) inhibition at 24 hours. The absolute bioavailability of olmesartan medoxomil is approximately 26\%, and its antihypertensive effect is achieved within 1–2 hours, with maximal reduction of BP achieved within 4–6 hours. The volume of distribution of olmesartan medoxomil is approximately 17 L. Olmesartan medoxomil is highly bound to plasma proteins (99\%) and does not cross into red blood cells. It crosses the blood–brain barrier in rats poorly, but does cross the placental barrier and is distributed to the fetus. Olmesartan medoxomil is also distributed to milk at low levels in rats. Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, no further metabolism takes place. Approximately 35\%–50\% gets excreted in the urine unchanged, while the remainder is eliminated in feces via the bile. Olmesartan medoxomil, like other angiotensin II antagonists, also exerts significant BP-independent beneficial effects. It reduces the expression of nicotinamide adenine dinucleotide phosphate oxidase subunits, the major source of free oxygen radicals in blood vessels.

### Olmesartan medoxomil–amlodipine combination therapy

The efficacy and safety of olmesartan medoxomil–amlodipine combination therapy in the treatment of hypertension has been reported in several randomized controlled trials. In one trial,\textsuperscript{28,10,17}1017 patients with a baseline BP of 164/102 mmHg were given open-label amlodipine 5 mg daily as monotherapy. After eight weeks, the non-responders (n = 755) were randomized to receive placebo plus amlodipine 5 mg or a combination of olmesartan medoxomil (10–40 mg) with amlodipine 5 mg for eight weeks. At week 16, patients who had achieved diastolic BP <90 mmHg and/or systolic BP <140 mmHg continued on randomized treatment for a further eight weeks. Patients with both systolic BP and diastolic BP \(\geq 140/90\) mmHg at week 16 had their medication uptitrated to olmesartan medoxomil–amlodipine 20/5 mg, olmesartan medoxomil–amlodipine 40/5 mg, or olmesartan medoxomil–amlodipine 40/10 mg. The combination of olmesartan medoxomil 10–40 mg with amlodipine 5 mg for eight weeks reduced mean systolic BP/diastolic BP by up to 16.8 mmHg and 9.6 mmHg, respectively. The additional adjusted mean change in seated diastolic BP (primary endpoint) with last observation carried forward compared with placebo–amlodipine 5 mg was \(-2.0\) mmHg (\(P = 0.02\)), \(-3.7\) mmHg (\(P < 0.0001\)), and \(-3.8\) mmHg (\(P < 0.0001\)).
for olmesartan medoxomil–amlodipine 10/5 mg, 20/5 mg, and 40/5 mg, respectively.

In another randomized, double-blind, parallel-group, multicenter trial, 538 patients with moderate-to-severe hypertension (systolic BP/diastolic BP ≥ 160/100 mmHg) were given open-label olmesartan medoxomil 20 mg daily for eight weeks. At the end of eight weeks, patients whose BP was still above target (non-diabetics with systolic BP/diastolic BP ≥ 140/90 mmHg and diabetics with systolic BP/diastolic BP ≥ 130/80 mmHg) were assigned to amlodipine 5 or 10 mg/day or a placebo in addition to olmesartan medoxomil, in a double-blind design. After eight weeks (with last observation carried forward), the adjusted mean change in seated diastolic BP from baseline was −7.6 mmHg for olmesartan medoxomil–placebo, −10.4 mmHg for olmesartan medoxomil–amlodipine 20/5 mg (P = 0.0006) and −10.9 mmHg for olmesartan medoxomil–amlodipine 20/10 mg (P < 0.0001). Mean changes in seated systolic BP from baseline with olmesartan medoxomil–amlodipine 20/5 mg and olmesartan medoxomil–amlodipine 20/10 mg were −16.1 and −16.7 mmHg, respectively (P < 0.0001). Achievement of BP goal rates was significantly higher with olmesartan medoxomil–amlodipine 20/5 mg and olmesartan medoxomil–amlodipine 20/10 mg (44.5% and 45.8%, respectively; P = 0.0011 and P = 0.0004) versus olmesartan medoxomil–placebo (28.5%). The incidence of drug-related adverse events was 8.9% for olmesartan medoxomil–placebo, 7.7% for olmesartan medoxomil–amlodipine 20/5 mg, and 11.3% for olmesartan medoxomil–amlodipine 20/10 mg (P = 0.490).

Chrysant et al30 randomized 1940 patients according to a double-blind, placebo-controlled, factorial design in the COACH (The Combination of Olmesartan medoxomil and Amlodipine besylate in Controlling High blood pressure) trial. Mean age of the study population was 54.0 years, 54.3% were men, and 19.8% were aged ≥ 65 years. The mean baseline BP was 164/102 mmHg, and 79.3% of patients had Stage 2 hypertension. Patients were randomized to receive either an olmesartan medoxomil–amlodipine combination, olmesartan medoxomil alone, or amlodipine alone. The combination of olmesartan medoxomil–amlodipine caused dose-dependent reductions in seated systolic BP (from −13.8 mmHg with olmesartan medoxomil–amlodipine 10/5 mg to −19.0 mmHg with olmesartan medoxomil–amlodipine 40/10 mg) and seated systolic BP (from −23.6 mmHg with olmesartan medoxomil–amlodipine 20/5 mg to −30.1 mmHg with olmesartan medoxomil–amlodipine 40/10 mg) that were significantly greater than the reductions with the corresponding component monotherapies (P < 0.001). The number of patients achieving the BP goal ranged from 57/163 (35.0%) to 84/158 (53.2%) in the combination therapy group, from 32/160 (20.0%) to 58/160 (36.3%) in the olmesartan medoxomil monotherapy group, and from 34/161 (21.1%) to 53/163 (32.5%) in the amlodipine monotherapy group (P < 0.005, combination therapy versus component monotherapies), compared with 14/160 (8.8%) in the placebo group. The results of this study are summarized in Table 3. The most common adverse events were edema (ranging from 9.9% for olmesartan medoxomil 20 mg to 36.8% for amlodipine 10 mg, compared with 12.3% for placebo) and headache (ranging from 2.5% for olmesartan medoxomil–amlodipine 10/5 mg to 8.7% for olmesartan medoxomil 20 mg, compared with 14.2% for placebo). These studies show that a fixed-dose combination of olmesartan medoxomil–amlodipine is effective and well tolerated, with an adverse effect profile similar to those of the individual drugs. Studies in special patient populations also confirm the efficacy and tolerability of this combination.

**Olmesartan medoxomil–amlodipine in specific populations**

A recently published COACH sub-study evaluated the long-term efficacy of the combination of amlodipine and olmesartan medoxomil with or without hydrochlorothiazide.31 The following findings were reported from this study and the subgroup analyses.

**Elderly patients**

Mean seated BP reductions for patients aged < and ≥ 65 years at week 52 were 31.0/19.2 mmHg and 38.3/21.5 mmHg, respectively. Baseline seated BP and reduction in seated BP reductions were greater in patients eventually titrated to amlodipine–olmesartan–hydrochlorothiazide 10/40/25 mg per day. In general, the addition of hydrochlorothiazide caused greater seated BP reduction in patients aged ≥ 65 years. Patients aged ≥ 65 years had greater reductions in seated systolic BP at each titration step, compared with patients aged < 65 years.

**Black patients**

Mean seated BP reduction at week 52 for black and non-black patients was 30.8/18.7 mmHg and 33.0/20.0 mmHg, respectively. Once again, baseline seated BP was highest and seated systolic BP reduction greatest in patients titrated to amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/25 mg per day. Approximately 20% of black patients...
remained on the initial dose of amlodipine–olmesartan medoxomil 5/40 mg per day, compared with 34.9% of nonblacks. More black patients required titration to higher doses than nonblacks. Among black patients, 35.9% were uptitrated to amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/25 mg per day, and 49.7% on this dose achieved their seated BP goal at week 52. Among black patients, the greatest seated BP reduction was observed in patients switching from amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/12.5 mg per day to amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/25 mg per day.

Patients with diabetes

At week 52, seated BP reduction from baseline in patients with diabetes was 34.2/19.9 mmHg compared with 32.1/19.6 mmHg in patients without diabetes. Only 26.9% of patients with diabetes achieved the seated BP goal of <130/80 mmHg, whereas 72.9% of patients without diabetes achieved their seated BP goal of <140/90 mmHg with the initial dose of amlodipine–olmesartan medoxomil 5/40 mg per day. By week 52, 48.0% of patients with diabetes were uptitrated to amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/25 mg per day, and 21.1% achieved the seated BP goal of <130/80 mmHg.

In summary, the overall percentage of patients achieving their BP goal at week 52 on the combination of amlodipine–olmesartan medoxomil was 61.0% for patients aged ≥ 65 years, 68.1% for patients aged < 65 years, 63.3% for blacks, 67.8% for nonblacks, 26.9% for patients with diabetes, and 72.9% of patients without diabetes. However, the study was not powered to show statistically significant differences between subgroups. Combination therapy was well tolerated, and no safety issues were noted. The most common adverse events were edema (ranging from 9.9% with olmesartan medoxomil 20 mg to 36.8% with amlodipine 10 mg, compared with 12.3% with placebo) and headache (ranging from 2.5% with olmesartan medoxomil–amlodipine 10/5 mg to 8.7% with olmesartan medoxomil 20 mg, compared with 14.2% for placebo). Specifically, drug-related edema occurred in 7.0%, 11.1%, 9.1%, and 10.7% of patients receiving amlodipine–olmesartan medoxomil 5/40 mg per day, amlodipine–olmesartan medoxomil 10/40 mg per day, amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/12.5 mg per day, and amlodipine–olmesartan medoxomil–hydrochlorothiazide 10/40/25 mg per day, respectively.

Another study in 692 patients reported that co-administration of olmesartan medoxomil and amlodipine with a thiazide diuretic was better in achieving target BP, especially when a higher dose of the diuretic was used. Patients with moderate-to-severe hypertension who were inadequately controlled (BP > 140/90 mmHg) with amlodipine 5 mg/day monotherapy and who subsequently completed 16 weeks of double-blind combination treatment with olmesartan medoxomil–amlodipine entered a 28-week open-label phase in which all patients initially received olmesartan medoxomil–amlodipine 40/5 mg/day. After four, 10, and 19 weeks, patients with inadequate BP control had their doses increased in a stepwise manner to olmesartan medoxomil–amlodipine 40/10 mg, olmesartan medoxomil–amlodipine–hydrochlorothiazide 40/10/12.5 mg, and olmesartan medoxomil–amlodipine–hydrochlorothiazide 40/10/25 mg. Overall, 66.9% of patients achieved the target BP systolic BP < 140 mmHg and diastolic BP < 90 mmHg for patients without diabetes, and systolic BP < 130 mmHg and diastolic BP < 80 mmHg for patients with diabetes.

Daiichi Sankyo, Inc. markets the combination of amlodipine–olmesartan medoxomil as AZOR®. The different dose combinations of amlodipine–olmesartan medoxomil available in the US and Europe are 5/20, 10/20, 5/40, and 10/40 mg. Although monotherapy can be directly switched to fixed-dose combination, it is recommended to titrate the individual components separately until a suitable dose of each drug is established before switching to the fixed-dose combination. Caution and close monitoring of potassium and creatinine is needed while titrating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers containing

---

**Table 3 Proportion of patients achieving target blood pressure (<140/90 mmHg or <130/80 mmHg in patients with diabetes mellitus) by week eight/last observation carried forward according to subgroup and treatment regimen**

<table>
<thead>
<tr>
<th>Goal BP achieved (%)</th>
<th>Age &lt;65</th>
<th>≥65</th>
<th>Race Black</th>
<th>Nonblack</th>
<th>Diabetes status DM</th>
<th>non-DM</th>
<th>BMI &lt;30 kg/m²</th>
<th>≥30 kg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>10.9</td>
<td>0</td>
<td>4.4</td>
<td>10.4</td>
<td>8.7</td>
<td>8.8</td>
<td>12.0</td>
<td>7.3</td>
</tr>
<tr>
<td>Amlodipine 10 mg</td>
<td>32.8</td>
<td>31.1</td>
<td>43.6</td>
<td>29.0</td>
<td>8.7</td>
<td>36.4</td>
<td>30.3</td>
<td>34.4</td>
</tr>
<tr>
<td>Olmesartan 40 mg</td>
<td>41.1</td>
<td>16.1</td>
<td>15.9</td>
<td>44.0</td>
<td>9.5</td>
<td>40.3</td>
<td>47.9</td>
<td>30.0</td>
</tr>
<tr>
<td>Amlodipine–olmesartan (10/40 mg)</td>
<td>56.3</td>
<td>21.2</td>
<td>38.2</td>
<td>52.0</td>
<td>12.5</td>
<td>55.5</td>
<td>53.3</td>
<td>46.0</td>
</tr>
</tbody>
</table>

**Abbreviations:** DM, diabetes mellitus; BMI, body mass index; BP, blood pressure.
fixed-dose combinations. Dosage may be increased after two weeks, and a smaller dose combination should be chosen for elderly patients (>65 years) and patients with chronic kidney disease. No specific data exist on drug interactions of this fixed-dose combination, and the guidelines for the individual components should be followed.

Peripheral edema was found to be significantly less common for olmesartan medoxomil–amlodipine 40/10 mg per day than for amlodipine monotherapy 5 mg/day.28 A controversial effect of olmesartan medoxomil is that it improves myocardial function independent of BP reduction in hypertensive patients. Attenuation of inflammatory changes and myocardial hypertrophy may play an important role.33 Rosendorff et al14 randomized 102 patients with hypertension, left ventricular hypertrophy, and vascular hypertrophy to either amlodipine or olmesartan for 52 weeks in a Phase IIIb study. Add-on hydrochlorothiazide and terazosin were allowed if needed to achieve the target BP (<140/90 mmHg for non-diabetics and <135/85 mmHg for diabetics). At the end of 52 weeks, there were no significant changes in left ventricular compliance or carotid or femoral artery wall-to-lumen ratios in either treatment group.

Summary

Hypertension is the leading cause of cardiovascular disease morbidity and mortality. Despite the availability of many effective antihypertensive agents, only 37% of the hypertensive patients achieve their target BP. Most patients with Stage 2 or higher hypertension and those with a high risk of cardiovascular disease require more than one agent to control their BP. Experts recommend initiating antihypertensive therapy using a combination of agents with complementary mechanisms of action in these patients. In long-term treatment of hypertension, single-pill combinations are associated with better drug adherence and better outcomes in comparison with free drug combinations.

Several randomized studies have demonstrated the superiority of using combination drug therapy, especially calcium channel blockers and the angiotensin II antagonists, in achieving target BP in various subgroups, while minimizing the incidence of adverse events seen with the treatment of hypertension using higher doses of a single agent. Addition of a thiazide diuretic to a calcium channel blocker, and a renin angiotensin aldosterone system antagonist combination further potentiates the antihypertensive effects of these drugs.

Disclosure

The authors report no conflicts of interest in this work.

References

22. Mason RP, Campbell SF, Wang SD, Herbeete LG. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlopidine with unchanged drugs of this class in cardiac membranes. Mol Pharmacol. 1989;36:634–640.


